Literature DB >> 31732285

Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.

Xiaoxuan Zhuang1, Eric O Long2.   

Abstract

The promise of natural killer (NK) cells as effectors in cancer cellular therapy is limited by their expression of dominant inhibitory receptors for human leukocyte antigen (HLA) class I. Here, we discuss how chimeric antigen receptors (CARs) engineered to override inhibitory signaling might boost NK cell antitumor responses, independently of blockade of NK cell inhibitory receptors. Published by Elsevier Ltd.

Entities:  

Year:  2019        PMID： 31732285     DOI： 10.1016/j.it.2019.10.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  2 in total

1.  CRISPR Screen to Identify Factors that Render Tumor Cells Sensitive or Resistant to Killing by NK Cells.

Authors:  Xiaoxuan Zhuang; Eric O Long
Journal:  Methods Mol Biol       Date:  2022

2.  NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.

Authors:  Xiaoxuan Zhuang; Eric O Long
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.